From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
In diagnostic workflows, AI is enabling:
complex datasets—an undertaking that requires advanced bioinformatics and AI. As the field evolves, data integration becomes as critical as data generation. 12
• Radiomics – Extracting hundreds of quantitative features from CT or MRI images to noninvasively assess tumor biology 7 • Real-time image analysis – Supporting intra- operative decisions and improving biopsy targeting 8 • Predictive analytics – Tracking minimal residual disease (MRD) via liquid biopsy signals such as somatic copy number alterations (SCNAs) or epigenetic markers 9 • Treatment selection support – Analyzing clinical trial data, molecular profiles, and patient-specific variables to recommend tailored therapies based on real-time evidence. AI accelerates discovery, enhances accuracy, and supports scalability—but must be explainable, validated, and regulated for clinical use. 10 Beyond Genomics: Embracing Multi-Omics Disease biology is inherently dynamic, shaped by layered interactions across DNA, RNA, proteins, metabolites, epigenetics, and the microbiome. By leveraging next-generation sequencing, multi-omics enables the simultaneous analysis of genomic, epigenomic, transcriptomic, and proteomic data, often from a single sample. This integrative approach yields deeper biological insights than single-omic analyses alone. 11 Emerging tools like cfDNA fragmentomics further enhance precision, revealing fragmentation patterns in circulating tumor DNA that can aid early detection and monitor MRD. Yet, the true power of multi-omics lies in the ability to synthesize these
Imaging Innovation: Seeing Cancer Differently
New imaging technologies are dramatically enhancing both the resolution and functional context of tumor detection, taking precision oncology to new heights. Techniques such as super-resolution microscopy (e.g., STED and SIM) allow researchers to visualize cancer cell behavior at the molecular level, 13 revealing critical details about metastasis, drug resistance and cell signaling. High-content screening and single-cell imaging are enabling the discovery and devel- opment of more targeted, effective therapies by capturing cellular heterogeneity in unprece- dented detail. Theranostics—combining diagnostic imaging with targeted therapy, such as PET-guided radionuclide delivery—further exemplifies how imaging can drive both detection and treatment within a unified workflow. 14 When paired with artificial intelligence, these imaging platforms become even more powerful. AI enhances pattern recognition, automates feature extraction, and supports personalized diagnostic interpretation. It enables clinicians to stratify patients more accurately, guide biopsy or surgical decisions in real time and monitor therapeutic response with greater granularity. Together, AI and advanced imaging are pushing the boundaries of cancer care—enabling earlier
36 | GENengnews.com
Powered by FlippingBook